

Flow Trial Schedule 2026-2027

Accredited Programmes	Trial Issues	APR 26	MAY 26	JUN 26	JUL 26	AUG 26	SEP 26	OCT 26	NOV 26	DEC 26	JAN 27	FEB 27	MAR 27
CD34 Stem Cell Enumeration	6	X		X		X		X		X		X	
Immune Monitoring	6		X		X		X		X		X		X
Leukaemia Immunophenotyping	6	X		X		X		X		X		X	
Leukaemia Diagnostic Interpretation	6		X		X		X		X		X		X
Low Level Leucocyte Enumeration	6		X		X		X		X		X		X
Measurable Residual Disease for ALL by Flow Cytometry	4		X			X			X			X	
Paroxysmal Nocturnal Haemoglobinuria	6	X		X		X		X		X		X	
Non-accredited Programmes	Trial Issues	APR 26	MAY 26	JUN 26	JUL 26	AUG 26	SEP 26	OCT 26	NOV 26	DEC 26	JAN 27	FEB 27	MAR 27
CD19 CAR-T Cell Monitoring by Flow Cytometry	1								X				
Cerebrospinal Fluid Immunophenotyping Programme	3		X				X				X		
Haematological Malignancy Bone Marrow Aspirate Assessment	3			X				X				X	
Measurable Residual Disease for AML by Flow Cytometry	4			X			X		X				X
Measurable Residual Disease for CLL by Flow Cytometry	4	X			X			X			X		
Measurable Residual Disease for Plasma Cell Myeloma by Flow Cytometry	3	X			X ¹					X			

1. Electronic round only

Please note that this is a guide only. UK NEQAS for Leucocyte Immunophenotyping reserves the right to cancel or vary the number of shipments. Please note that your participation entitles you to the service and not the number of shipments.

Sheffield Teaching Hospitals NHS Foundation Trust, a UKAS proficiency testing provider No. 7804, operating UK NEQAS for Leucocyte Immunophenotyping.

Molecular Haemato-Oncology Trial Schedule 2026 – 2027

Accredited Programmes	Trial issue	APR 26	MAY 26	JUN 26	JUL 26	AUG 26	SEP 26	OCT 26	NOV 26	DEC 26	JAN 27	FEB 27	MAR 27
<i>BCR::ABL1</i> and AML Translocation Identification	3	X				X				X			
<i>BCR::ABL1</i> Kinase Domain Variant (Mutation) Status	3			X				X				X	
<i>BCR::ABL1</i> Major Quantification	3		X				X				X		
<i>BCR::ABL1</i> Minor Quantification	3		X				X				X		
<i>BRAF</i> p.Val600Glu (V600E) Mutation Status for Hairy Cell Leukaemia	3	X			X					X			
<i>FLT3</i> Mutation Status	3				X				X				X
IG/TCR Clonality Status	3	X				X				X			
<i>KIT</i> p.Asp816Val (D816V) Mutation Status for Mast Cell Disease	3		X				X				X		
Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinaemia	3			X				X					X
Myeloproliferative Neoplasms Diagnostic Testing ¹	4		X			X			X			X	
<i>NPM1</i> Mutation Status	3				X				X				X
Paediatric Acute Leukaemia Translocations	3			X				X				X	
Post-Stem Cell Transplant Chimerism Monitoring	5		X		X			X		X		X	

Non-accredited Programmes	Trial Issue	APR 26	MAY 26	JUN 26	JUL 26	AUG 26	SEP 26	OCT 26	NOV 26	DEC 26	JAN 27	FEB 27	MAR 27
Lymphoid Gene Panels	2						X ²						X ³
Measurable Residual Disease for Acute Myeloid Leukaemia by Molecular Methods	2					X							X
Measurable Residual Disease for Lymphoid Neoplasms by Molecular Methods	2			X					X				
Myeloid Gene Panels	2					X ²						X ³	

1. Please note, only the JAK2 p.V617F aspect of testing is currently accredited. We are working towards accreditation for the other markers. 2. Includes educational variant interpretation; 3. Technical focus.

Please note that this is a guide only. UK NEQAS for Leucocyte Immunophenotyping reserves the right to cancel or vary the number of shipments. Please note that your participation entitles you to the service and not the number of shipments.

Author(s): Stuart Scott

Sheffield Teaching Hospitals NHS Foundation Trust, a UKAS accredited proficiency testing provider No. 7804, operating UK NEQAS for Leucocyte Immunophenotyping.